{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:32:55Z","timestamp":1784835175588,"version":"3.55.0"},"reference-count":77,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Inborn errors of metabolism (IEMs) are a group of disorders resulting from defects in enzymes in metabolic pathways. These disorders impact the processing of metabolites, leading to a wide array of effects on each organ system. Advances in genetic screening have allowed for the early identification and intervention of IEMs, traditionally in the form of enzyme replacement or vitamin supplementation. However, many IEMs disrupt essential metabolic pathways where simple supplementation proves ineffective, resulting in substantial disease burden. In the case of renal IEMs, metabolic pathway disruption leads to the onset of chronic kidney disease (CKD). For these diseases, genetic therapy provides hope. Over the past few decades, the technology for genetic therapy has emerged as a promising solution to these disorders. These therapies aim to correct the source of the defect in the genetic code so that patients may live full, unencumbered lives. In this review, we searched a large database to identify IEMs that affect the kidney and investigated the current landscape and progression of gene therapy technology. Multiple promising genetic therapies were identified for IEMs affecting the kidney, including primary hyperoxaluria, argininemia, glycogen storage diseases Ia and Ib, and Fabry disease. Emerging gene therapy approaches using adeno-associated virus (AAV) vectors, lentiviral vectors, and CRISPR\/Cas9 techniques hold promising potential to provide curative treatments for additional single-mutation disorders.<\/jats:p>","DOI":"10.3390\/genes16050516","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T11:00:54Z","timestamp":1745924454000},"page":"516","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Updated Gene Therapy for Renal Inborn Errors of Metabolism"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2235-5613","authenticated-orcid":false,"given":"Sean","family":"Hergenrother","sequence":"first","affiliation":[{"name":"Department of Medicine, Northeast Ohio Medical University, Rootstown, OH 44272, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Husein","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northeast Ohio Medical University, Rootstown, OH 44272, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cole","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northeast Ohio Medical University, Rootstown, OH 44272, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Kalina","sequence":"additional","affiliation":[{"name":"Department of Medicine, Northeast Ohio Medical University, Rootstown, OH 44272, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3892-8376","authenticated-orcid":false,"given":"Rupesh","family":"Raina","sequence":"additional","affiliation":[{"name":"Akron Nephrology Associates, Cleveland Clinic Akron General Medical Center, Akron, OH 44307, USA"},{"name":"Department of Nephrology, Akron Children\u2019s Hospital, Akron, OH 44308, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/jimd.12442","article-title":"100 years of inherited metabolic disorders in Austria\u2014A national registry of minimal birth prevalence, diagnosis, and clinical outcome of inborn errors of metabolism in Austria between 1921 and 2021","volume":"45","author":"Ramoser","year":"2022","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"s10","DOI":"10.1590\/1806-9282.66.s1.10","article-title":"Fabry disease: Genetics, pathology, and treatment","volume":"66","author":"Bernardes","year":"2020","journal-title":"Rev. Assoc. Med. Bras."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/adc.2005.091637","article-title":"The incidence of inherited metabolic disorders in the West Midlands, UK","volume":"91","author":"Sanderson","year":"2006","journal-title":"Arch. Dis. Child."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s12098-021-03759-9","article-title":"Inborn Errors of Metabolism-Approach to Diagnosis and Management in Neonates","volume":"88","author":"Balakrishnan","year":"2021","journal-title":"Indian J. Pediatr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e3721","DOI":"10.1002\/jgm.3721","article-title":"Gene therapy clinical trials worldwide to 2023-an update","volume":"26","author":"Ginn","year":"2024","journal-title":"J. Gene Med."},{"key":"ref_6","unstructured":"Jeanmonod, R., Asuka, E., and Jeanmonod, D. (2025). Inborn Errors of Metabolism. StatPearls, StatPearls Publishing."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1651-2227.2004.tb03050.x","article-title":"Inborn errors of metabolism: An update on epidemiology and on neonatal-onset hyperammonemia","volume":"93","author":"Deodato","year":"2004","journal-title":"Acta Paediatr. Suppl."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.21037\/atm.2018.12.12","article-title":"Amino acid disorders","volume":"6","author":"Aliu","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13023-024-03021-3","article-title":"Late-onset methylmalonic acidemia and homocysteinemia (cblC disease): Systematic review","volume":"19","author":"Arhip","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_10","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993). Disorders of Intracellular Cobalamin Metabolism. GeneReviews\u00ae, University of Washington, Seattle."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1089\/hum.2019.113","article-title":"Gene Therapy for Methylmalonic Acidemia: Past, Present, and Future","volume":"30","author":"Chandler","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.omtm.2022.09.001","article-title":"Systemic gene therapy for methylmalonic acidemia using the novel adeno-associated viral vector 44.9","volume":"27","author":"Chandler","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.omtm.2021.04.005","article-title":"Central nervous system-targeted adeno-associated virus gene therapy in methylmalonic acidemia","volume":"21","author":"May","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1681\/ASN.2009080808","article-title":"Phenotype and genotype characterization of adenine phosphoribosyltransferase deficiency","volume":"21","author":"Dollinger","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ekir.2019.04.021","article-title":"Adenine Phosphoribosyltransferase Deficiency: A Potentially Reversible Cause of CKD","volume":"4","author":"Li","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"ref_16","first-page":"403","article-title":"Adenine phosphoribosyl transferase deficiency leads to renal allograft dysfunction in kidney transplant recipients: A systematic review","volume":"44","author":"Rashid","year":"2022","journal-title":"J. Bras. Nefrol."},{"key":"ref_17","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993). Lysinuric Protein Intolerance. GeneReviews\u00ae, University of Washington, Seattle."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13023-016-0550-8","article-title":"Update on Lysinuric Protein Intolerance, a Multi-faceted Disease Retrospective cohort analysis from birth to adulthood","volume":"12","author":"Mauhin","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ajmg.c.30287","article-title":"Lysinuric protein intolerance: Reviewing concepts on a multisystem disease","volume":"157C","author":"Sebastio","year":"2011","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bodoy, S., Sotillo, F., Espino-Guarch, M., Sperandeo, M.P., Ormazabal, A., Zorzano, A., Sebastio, G., Artuch, R., and Palac\u00edn, M. (2019). Inducible Slc7a7 Knockout Mouse Model Recapitulates Lysinuric Protein Intolerance Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215294"},{"key":"ref_21","first-page":"83","article-title":"Hyperargininemia: A Family with a Novel Mutation in an Unexpected Site","volume":"5","author":"Cohen","year":"2011","journal-title":"JIMD Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajmg.c.30091","article-title":"Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency","volume":"142C","author":"Scaglia","year":"2006","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/gt.2012.99","article-title":"AAV-based gene therapy prevents neuropathology and results in normal cognitive development in the hyperargininemic mouse","volume":"20","author":"Lee","year":"2013","journal-title":"Gene Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/gt.2014.106","article-title":"Minimal ureagenesis is necessary for survival in the murine model of hyperargininemia treated by AAV-based gene therapy","volume":"22","author":"Hu","year":"2015","journal-title":"Gene Ther."},{"key":"ref_25","unstructured":"Stone, W.L., John, T.A., Anastasopoulou, C., Basit, H., and Adil, A. (2025). Glycogen Storage Disease. StatPearls, StatPearls Publishing."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1038\/gim.2014.128","article-title":"Diagnosis and management of glycogen storage disease type I: A practice guideline of the American College of Medical Genetics and Genomics","volume":"16","author":"Kishnani","year":"2014","journal-title":"Genet. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/mt.2010.119","article-title":"Neonatal Gene Therapy of Glycogen Storage Disease Type Ia Using a Feline Immunodeficiency Virus\u2013based Vector","volume":"18","author":"Grinshpun","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1007\/BF02679996","article-title":"Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a","volume":"161","author":"Chou","year":"2002","journal-title":"Eur. J. Pediatr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S404","DOI":"10.1016\/j.ymthe.2004.06.999","article-title":"1054. Development of Adeno-Associated Virus (AAV) Vectors for Gene Therapy in the Mouse Model for Glycogen Storage Disease Type Ia (GSD-Ia)","volume":"9","author":"Koeberl","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e70014","DOI":"10.1002\/jimd.70014","article-title":"Safety and Efficacy of DTX401, an AAV8-Mediated Liver-Directed Gene Therapy, in Adults With Glycogen Storage Disease Type I a (GSDIa)","volume":"48","author":"Weinstein","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1093\/hmg\/ddx325","article-title":"Liver-directed gene therapy for murine glycogen storage disease type Ib","volume":"26","author":"Kwon","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.pedneo.2017.11.006","article-title":"Fructose-1,6-bisphosphatase deficiency as a cause of recurrent hypoglycemia and metabolic acidosis: Clinical and molecular findings in Malaysian patients","volume":"59","author":"Moey","year":"2018","journal-title":"Pediatr. Neonatol."},{"key":"ref_33","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993). Fructose-1,6-Bisphosphatase Deficiency. GeneReviews\u00ae, University of Washington, Seattle."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mantle, D., Millichap, L., Castro-Marrero, J., and Hargreaves, I.P. (2023). Primary Coenzyme Q10 Deficiency: An Update. Antioxidants, 12.","DOI":"10.3390\/antiox12081652"},{"key":"ref_35","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993). Primary Coenzyme Q10 Deficiency Overview. GeneReviews\u00ae, University of Washington, Seattle."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Xie, J., Jiang, J., and Guo, Q. (2021). Primary Coenzyme Q10 Deficiency-7 and Pathogenic COQ4 Variants: Clinical Presentation, Biochemical Analyses, and Treatment. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.776807"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Barriocanal-Casado, E., Cueto-Ure\u00f1a, C., Benabdellah, K., Guti\u00e9rrez-Guerrero, A., Cobo, M., Hidalgo-Guti\u00e9rrez, A., Rodr\u00edguez-Sevilla, J.J., Mart\u00edn, F., and L\u00f3pez, L.C. (2016). Gene Therapy Corrects Mitochondrial Dysfunction in Hematopoietic Progenitor Cells and Fibroblasts from Coq9R239X Mice. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158344"},{"key":"ref_38","first-page":"1560","article-title":"GRACILE syndrome\u2014A severe neonatal mitochondrial disorder","volume":"128","author":"Fellman","year":"2012","journal-title":"Duodecim"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3109\/0886022X.2014.900422","article-title":"BCS1L gene mutation causing GRACILE syndrome: Case report","volume":"36","author":"Kasapkara","year":"2014","journal-title":"Ren. Fail."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/nep.14086","article-title":"Identification of two novel variants of BCS1L gene in a patient with classical GRACILE syndrome","volume":"27","author":"Guo","year":"2022","journal-title":"Nephrology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1258\/acb.2011.011180","article-title":"BCS1L gene mutation presenting with GRACILE-like syndrome and complex III deficiency","volume":"49","author":"Lynn","year":"2012","journal-title":"Ann. Clin. Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wang, Y., Hu, L.-F., Zhou, T.-J., Qi, L.-Y., Xing, L., Lee, J., Wang, F.-Z., Oh, Y.-K., and Jiang, H.-L. (2021). Gene therapy strategies for rare monogenic disorders with nuclear or mitochondrial gene mutations. Biomaterials, 277.","DOI":"10.1016\/j.biomaterials.2021.121108"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s13311-013-0177-6","article-title":"Mitochondrial DNA Depletion Syndromes: Review and Updates of Genetic Basis, Manifestations, and Therapeutic Options","volume":"10","author":"Scaglia","year":"2013","journal-title":"Neurotherapeutics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.mito.2009.08.003","article-title":"Dystonia and deafness due to SUCLA2 defect; Clinical course and biochemical markers in 16 children","volume":"9","author":"Morava","year":"2009","journal-title":"Mitochondrion"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.kint.2019.11.023","article-title":"Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening","volume":"97","author":"Sas","year":"2020","journal-title":"Kidney Int."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Wood, K.D., Freeman, B.L., Killian, M.E., Lai, W.S., Assimos, D., Knight, J., and Fargue, S. (2021). Effect of alanine supplementation on oxalate synthesis. Biochim. Biophys. Acta Mol. Basis Dis., 1867.","DOI":"10.1016\/j.bbadis.2020.165981"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/mt.2010.270","article-title":"Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer","volume":"19","author":"Salido","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/mt.2016.4","article-title":"Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1","volume":"24","author":"Dutta","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/jmedgenet-2022-108490","article-title":"Endocrine and behavioural features of Lowe syndrome and their potential molecular mechanisms","volume":"59","author":"Sena","year":"2022","journal-title":"J. Med. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s00467-016-3343-3","article-title":"The oculocerebrorenal syndrome of Lowe: An update","volume":"31","author":"Ludwig","year":"2016","journal-title":"Pediatr. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/hmg\/ddae045","article-title":"Base editing correction of OCRL in Lowe syndrome: ABE-mediated functional rescue in patient-derived fibroblasts","volume":"33","author":"Chen","year":"2024","journal-title":"Hum. Mol. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","article-title":"Lentivirus-mediated gene therapy for Fabry disease","volume":"12","author":"Khan","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Wan, Z., Wang, W., Zheng, S., Han, R., Xie, X., Zhao, Y., Wang, W., Sun, S., and Ye, L. (2023). Nonclassic Adrenal Hyperplasia (NCAH) due to 21-hydroxylase deficiency: A cohort of 78 patients. J. Steroid Biochem. Mol. Biol., 225.","DOI":"10.1016\/j.jsbmb.2022.106192"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1507\/endocrj.EJ16-0112","article-title":"Extra-adrenal induction of Cyp21a1 ameliorates systemic steroid metabolism in a mouse model of congenital adrenal hyperplasia","volume":"63","author":"Naiki","year":"2016","journal-title":"Endocr. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/hum.2017.203","article-title":"Biology of the Adrenal Gland Cortex Obviates Effective Use of Adeno-Associated Virus Vectors to Treat Hereditary Adrenal Disorders","volume":"29","author":"Markmann","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"107683","DOI":"10.1016\/j.ymgme.2023.107683","article-title":"Clinical and biochemical footprints of inherited metabolic diseases. XIV. Metabolic kidney diseases","volume":"140","author":"Schumann","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000521148","article-title":"Renal Phenotype in Mitochondrial Diseases: A Multicenter Study","volume":"8","author":"Parasyri","year":"2022","journal-title":"Kidney Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00467-012-2245-2","article-title":"Renal dysfunction in methylmalonic acidurias: Review for the pediatric nephrologist","volume":"28","author":"Morath","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00467-012-2329-z","article-title":"Hereditary causes of kidney stones and chronic kidney disease","volume":"28","author":"Edvardsson","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00467-018-4109-x","article-title":"Long-term renal outcomes of APRT deficiency presenting in childhood","volume":"34","author":"Runolfsdottir","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s13312-020-1825-7","article-title":"Urolithiasis due to Hereditary Xanthinuria Type II: A Long-term Follow-up report","volume":"57","author":"Kubihal","year":"2020","journal-title":"Indian Pediatr."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.humpath.2016.12.021","article-title":"Renal involvement in lysinuric protein intolerance: Contribution of pathology to assessment of heterogeneity of renal lesions","volume":"62","author":"Krug","year":"2017","journal-title":"Hum. Pathol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"14262","DOI":"10.1021\/acsnano.0c03850","article-title":"Synthetically Engineered Adeno-Associated Virus for Efficient, Safe, and Versatile Gene Therapy Applications","volume":"14","author":"Lugin","year":"2020","journal-title":"ACS Nano"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1615\/CritRevEukaryotGeneExpr.2023048135","article-title":"Adeno-Associated Virus-Mediated Gene Therapy","volume":"33","author":"Zaman","year":"2023","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Zwi-Dantsis, L., Mohamed, S., Massaro, G., and Moeendarbary, E. (2025). Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy. Viruses, 17.","DOI":"10.3390\/v17020239"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current Clinical Applications of In Vivo Gene Therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00439-006-0165-6","article-title":"Treatment of human disease by adeno-associated viral gene transfer","volume":"119","author":"Warrington","year":"2006","journal-title":"Hum. Genet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1038\/s41467-022-30880-w","article-title":"Neonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice","volume":"13","author":"Pontoizeau","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1089\/hum.2024.094","article-title":"Lentiviral Vector-Mediated Ex Vivo Hematopoietic Stem Cell Gene Therapy for Mucopolysaccharidosis IVA Murine Model","volume":"35","author":"Celik","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00467-021-05352-w","article-title":"The potential of RNA-based therapy for kidney diseases","volume":"38","author":"Bondue","year":"2023","journal-title":"Pediatr. Nephrol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41581-023-00702-3","article-title":"Cell and gene therapy for kidney disease","volume":"19","author":"Peek","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/jimd.12709","article-title":"Liver-directed gene therapy for inherited metabolic diseases","volume":"47","author":"Baruteau","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1089\/hum.2019.151","article-title":"Current Status on Clinical Development of Adeno-Associated Virus-Mediated Liver-Directed Gene Therapy for Inborn Errors of Metabolism","volume":"30","author":"Ginocchio","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bjh.18179","article-title":"Haematopoietic stem cell gene therapy in inborn errors of metabolism","volume":"198","author":"Chiesa","year":"2022","journal-title":"Br. J. Haematol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/5\/516\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:23:44Z","timestamp":1760030624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/5\/516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":77,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["genes16050516"],"URL":"https:\/\/doi.org\/10.3390\/genes16050516","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}